TCR² Presenting Therapies at Jeffreys Summit of Cell and Genetics

Cambridge, Massachusetts, September 26, 2022 (The Globe Newswire) – TCR2 Therapeutics Inc. announced. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of new T-cell therapies for patients with solid tumors, today announced that the management will participate in a live talk at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00 Evening Eastern Time

A live broadcast of the presentation will be available on the Investors page of the Company’s website An archived replay will be available for at least 30 days after your presentation.

Around TCR2 healing

Read:I’m an infectious disease expert – crucial reasons why I think monkeypox will become an ‘established STD’ explained

TCR2 Therapeutics Inc. is a clinical-stage cell therapy company that is developing a pipeline of novel T-cell therapies for patients with solid tumors. The company is focused on discovering and developing candidate products against new and complex targets using its proprietary T-cell receptor (TCR) Fusion Construct T cells (TRuC).®-T cells). The TRuC platform is designed to specifically recognize and kill tumor cells by fully harnessing the signals from the TCR, independent of human leukocyte antigen (HLA). For more information about TCR2Please visit

Investor And the The media Contact:
Karl Mauch
Senior Manager, Investor Relations and Corporate Communication
(617) 949-5667
[email protected]

Read:Risk of cardiovascular pathology determined using advanced cardiovascular imaging limited by heterogeneity amongst patients with human immunodeficiency virus

Previous post
Gary Neville: Matt Hancock provoked me into labor politics | Gary Neville
Next post
Dominic King: Trent Alexander-Arnold will be hurt after England’s latest omission